Dynavax Technologies (DVAX) Stock After the Bell on Dec. 24, 2025: Sanofi’s $2.2B Buyout, After‑Hours Action, and What to Watch Before the Next Market Open
Dynavax Technologies Corporation is the standout mover heading into the Christmas break after Sanofi agreed to acquire the vaccine maker in an all-cash deal valued at about $2.2 billion. The transaction price — $15.50 per share in cash — instantly re-framed DVAX from a “biotech fundamentals” story into a deal-arbitrage stock, with trading now anchored around the buyout price. Reuters+2PR Newswire+2